It seems incontrovertible that aberrant IGFBP7 promoter hypermethylation and simultaneous IGFBP7 gene silencing occurs in prostatic cancer cell lines, and the rate of IGFBP7 hypermethylation is significantly higher in cancer of the prostatic gland (60%) and high grade prostatic intraepithelial neoplasia (40%) than that in benign prostatic hyperplasia (15%) and histologically benign prostatic epithelium adjacent to the tumor (0%) (103). This evidence concerns the gene IGFBP7 and prostate cancer.